ReviewCurrent rheumatology reports2017
Chikungunya Virus-Associated Disease.
Review in Current rheumatology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Epidemiology, seroprevalence, and circulation of Chikungunya virus in Southern Africa (SADC region): A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- Trial
- Overview of Chikungunya Virus Epidemiology, Biology, and Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2027Review
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations.Bioinformatics and biology insights · 2025Article
- Correlates of disease severity in bluetongue as a model of acute arbovirus infection.PLoS pathogens · 2024Article
- Article
- Mono-ADP-ribosylation by PARP10 inhibits Chikungunya virus nsP2 proteolytic activity and viral replication.Cellular and molecular life sciences : CMLS · 2023Article
- Clinical manifestations of pain in patients suffering from COVID-19 infected with Delta variant of SARS-Cov-2.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- Article
- Article
- Role of Arbovirus Infection in Arthritogenic Pain Manifestation-A Systematic Review.Tropical medicine and infectious disease · 2022Review
- Structure of infective Getah virus at 2.8 Å resolution determined by cryo-electron microscopy.Cell discovery · 2022Article
- Human Genetic Host Factors and Its Role in the Pathogenesis of Chikungunya Virus Infection.Frontiers in medicine · 2022Review
- Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries.Journal of biomedical science · 2021Review
- Rediscovering the chikungunya virusBiomedica : revista del Instituto Nacional de Salud · 2021Review
- Mosquito-bite infection of humanized mice with chikungunya virus produces systemic disease with long-term effects.PLoS neglected tropical diseases · 2021Article
- Ferritin, Erythrocyte Sedimentation Rate, and C-Reactive Protein Level in Patients with Chikungunya-Induced Chronic Polyarthritis.The American journal of tropical medicine and hygiene · 2020Observational
- The effect of amantadine on an ion channel protein from Chikungunya virus.PLoS neglected tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChikungunya virus (CHIKV) infection has become increasingly prevalent in the last decade not only across the southern hemisphere but also, because of a recently documented viral mutation, in southern Europe and the USA. With the global spread of CHIKV infection, practitioners should know its epidemiology, pathophysiology and clinical features. RECENT
findingsThe acute phase of CHIKV disease is characterised by a fever-arthralgia-rash syndrome. Chronic rheumatic manifestations can persist for months to years with very variable clinical presentations. Some cases mimic inflammatory rheumatism such as rheumatoid arthritis. Several risk factors for persistent joint pain, notably older age, have been identified in cohort studies. Despite a low mortality rate with CHIKV infection, the rate of disability with chronic joint symptoms is high, and effective treatments are lacking. Current research is focusing on the development of vaccines and antiviral drugs, and data on treatment of CHIKV-induced chronic arthritis are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.